Navigation Links
Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:7/26/2010

LAKE FOREST, Ill., July 26 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

The controlled, randomized trial of patients on hemodialysis who have already been treated with Amgen's Epogen® (epoetin alfa), is taking place at 20 different hemodialysis centers across the United States. Patients in the trial will be treated with both Epogen and Hospira's EPO, with each patient receiving one drug first and then being switched to the second drug. The goal of the Phase I trial is to test safety and pharmacokinetics, or measurements of the drug's blood level and distribution in the body, compared with the reference product. Pending successful completion of the Phase I trial, Hospira would launch an expanded Phase III trial in 2011, also comparing safety and efficacy of Hospira's EPO with Epogen.

"This trial marks a key milestone for Hospira's biosimilars program," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "Congressional approval of a regulatory pathway for biosimilar drugs in the U.S. set the stage for our development of a U.S. biosimilar EPO. We hope to leverage our leadership in generics and our biosimilars experience in '/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Hospira TheraDoc(TM) Infection Control Assistant(TM) Documents Interventions to Help Hospital Reduce Catheter-Related Infections
2. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
3. Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.)
4. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
5. Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP
6. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
7. Hospira to Present at Citi 2010 Global Health Care Conference May 27, 2010
8. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
9. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
10. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
(Date:5/23/2013)... , May 23, 2013 More than half ... not benefit from chemotherapy and still have excellent outcomes. ... of one of the largest sources of online consumer ... and interactive Facebook page provide recently diagnosed women with ... safely avoid chemotherapy. "We anticipate these innovative ...
(Date:5/23/2013)... , May 23, 2013  Every day, their baby ... air to his lungs. April and Bryan Gionfriddo ... predictions weren,t true. "Quite a few doctors said ... alive," says April Gionfriddo , about her ... Anything that would work, we would take it and run ...
Breaking Medicine Technology:First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... 27, 2011 Ameritox (SM), the nation,s leader in ... Statement for the Record for the Congressional hearing on ... D Program," pointing to medication monitoring as a potential ... diversion and aiding in lowering national healthcare costs. The ...
... China, Oct. 27, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings ... a leading domestic developer, manufacturer and marketer of orthopedic ... to release third quarter 2011 financial results on November ... will hold a corresponding conference call and live webcast ...
Cached Medicine Technology:Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 2Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 3China Kanghui Holdings to Report Third Quarter 2011 Financial Results 2
(Date:5/25/2013)... According to an article in the June ... nearly 30 million Americans tan indoors each year and an ... knowing the health risks. New research suggests that UV ... on the brains of some tanners (Go to goo.gl/hdwnz). ... I can’t say that I fully support this contention from ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today ... lift skin on the neck, on the brow and under ... Aesthetics. , Ultherapy is a non-surgical procedure for the face ... to lift the skin over time. The use of FDA-cleared ... and then treat the deepest support layers of the skin ...
(Date:5/25/2013)... 2013 A disorder of the nerves, ... neuropathy. According to neuropathy expert doctor Helen C Lin, ... that the disorder affects almost 50% of all Diabetic ... Diabetes. The high blood sugar levels in the body ... from it usually tend to have abnormally high blood ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market (2012 – ... Materials, Packaging, & Geography: Trends & Forecasts” defines ... analysis and forecasting of the global revenue for ... restraining factors for the global food encapsulation markets ... market is segmented and revenue are forecasted on ...
(Date:5/25/2013)... 25, 2013 Absolute Surgical Specialists, serving Sun ... the NALA’s businesses throughout the country participating in Shop Local ... in the nationwide event as he understands what military families ... the Army. He said, “I wanted to give something back, ... but I live here too.” , Shop Local for a ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... ... HIV STOPS WITH US",is the message of ... across,the country including: Boston, Long Beach and Alameda ... positive people, and a,wide spectrum of HIV negative ... providers and partners talking about real issues., ...
... using widely available and inexpensive ultrasound imaging could help ... or other adverse cardiovascular events, according to a study ... Radiology . , Researchers performed ultrasound imaging on the ... at high risk for cardiovascular disease. Of those, ultrasound ...
... reduces bleeding problems, study finds , , MONDAY, Aug. 18 (HealthDay ... wrist rather than the groin reduces the incidence of bleeding ... using the radial artery in the wrist, is not widely ... almost 600,000 catheterizations in a national database, said a report ...
... Arizona hospitals can access the new AzHHA pharmacy benefit ... immediately see improvements to their bottom ... created and is,supported by the leading pharmacy benefit consulting ... rebate,reimbursements, implementation credits and many other options not typically,available ...
... 18 Today a representative of the,Executive Board ... Local,6434 ("ULTCW") filed a letter of complaint with ... the letter written to President Stern and the ... Vice President of ULTCW and,member of its Executive ...
... Aug. 18 Actavis Group, the,international generic ... approval from the U.S. Food & Drug ... 300mg. Distribution,of the product will commence immediately., ... in,300mg strength, are the generic equivalent of ...
Cached Medicine News:Health News:New HIV Prevention/Anti-Stigma Campaign Featuring HIV Positive & Negative Persons 'TOGETHER' Launches Across the Nation 2Health News:Ultrasound used to predict heart attack risk 2Health News:Reaching the Heart Through the Wrist 2Health News:Reaching the Heart Through the Wrist 3Health News:Arizona Hospital and Healthcare Association Teams Up with ARMSRx to Bring Cost Savings to Hospitals 2Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S. 2
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Siliconized PVC drains...
Bard® Channel Drain...
Used for placement of cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: